Iloperidone: A new drug for the treatment of schizophrenia

Arif, Sally A.; Mitchell, Melissa A.
February 2011
American Journal of Health-System Pharmacy;2/15/2011, Vol. 68 Issue 4, p301
Academic Journal
Purpose. The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety and tolerability profile of iloperidone for the treatment of schizophrenia are reviewed. Summary. Iloperidone is an atypical antipsychotic that recently received marketing approval from the Food and Drug Administration for the acute treatment of schizophrenia. Iloperidone is a pure antagonist and the first antipsychotic to have pharmacogenomic studies indicate predictive response based on six identifiedpolymorphisms. Pharmacokinetic studies have determined that iloperidone is well absorbed orally, with a bioavailability of 96%. Phase II and III clinical trials have shown iloperidone to improve symptoms of schizophrenia, based on the Positive and Negative Symptom Scale, Brief Psychiatric Rating Scale, and Clinical Global Impressions-Severity scores (p < 0.05). Iloperidone has established tolerability at recommended dosages of up to 24 mg daily; however, the dosage must be slowly increased over seven days, and twice-daily administration is required to avoid orthostatic hypotension. The most common adverse effects associated with iloperidone were dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight gain. Safety studies have also found that iloperidone increases the risk of Q-Tc interval prolongation, similar to that seen with ziprasidone. Minimal changes in glucose and lipid abnormalities were seen in short-term (4- and 6-week) and long-term (52-week) studies, indicating a low chance of metabolic disturbance with iloperidone. Conclusion. Iloperidone may be a viable and safe option for the treatment of schizophrenia in adult patients, especially for patients who cannot tolerate other antipsychotic agents. However, iloperidone lacks a clear benefit over other antipsychotic agents.


Related Articles

  • Iloperidone: Does it have a meaningful place in therapy?  // American Journal of Health-System Pharmacy;2/15/2011, Vol. 68 Issue 4, p297 

    No abstract available.

  • OLANZAPINE. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p620 

    The article presents information on olanzapine, an antipsychotic drug, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • PHENOTHIAZINES. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p660 

    The article presents information on phenothiazines, antipsychotic drugs, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Once-daily treatment of schizophrenia.  // Clinical Advisor;Apr2011, Vol. 14 Issue 4, p35 

    The article focuses on Latuda with lurasidone and its efficacy in schizophrenia. It mentions that the efficacy of lurasidone is mediated on a combination of central dopamine and serotonin receptor antagonism and is established in six-week placebo-controlled studies in adults. The study uses...

  • Antipsychotics/general anaesthetics/ mepivacaine/vecuronium bromide.  // Reactions Weekly;1/5/2013, Issue 1433, p9 

    The article describes the case of a 54-year-old man who experienced severe hypotension, ventricular fibrillation and cardiac arrest while receiving treatment with bromperidol, periciazine, fentanyl, propofol, sevoflurane, mepivacaine and vecuronium bromide.

  • Olanzapine-induced Orthostatic Hypotension. Jana, Amlan Kusum; Praharaj, Samir Kumar; Roy, Nirmalya // Clinical Psychopharmacology & Neuroscience;Apr2015, Vol. 13 Issue 1, p113 

    Olanzapine is an atypical antipsychotic which is efficacious in the treatment of schizophrenia. The adverse effect profile for olanzapine is benign except for higher rates of metabolic events. Orthostatic hypotension is less commonly reported with olanzapine as compared to first-generation and...

  • Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. Graff-Guerrero, Ariel; Rajji, Tarek K.; Mulsant, Benoit H.; Shinichiro Nakajima; Caravaggio, Fernando; Takefumi Suzuki; Hiroyuki Uchida; Gerretsen, Philip; Mar, Wanna; Pollock, Bruce G.; Mamo, David C. // JAMA Psychiatry;Sep2015, Vol. 72 Issue 9, p927 

    IMPORTANCE: Patients with late-life schizophrenia (LLS) are highly susceptible to antipsychotic adverse effects. Treatment guidelines endorse lower antipsychotic doses. However, the optimal dose of antipsychotics and associated dopamine D2/3 receptor (D2/3R) occupancies remain largely unexplored...

  • IN SESSION with Anil Malhotra, MD: Pharmacogenetics of Schizophrenia. Sussman, Norman // Primary Psychiatry;Jul2010, Vol. 17 Issue 7, p31 

    An interview with Doctor Anil Malhotra, director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, New York, is presented. When asked about the difference between genomics and pharmacogenetics, he states that pharmacogenetics refers to the effects of the treatment to a patient...

  • Schizophrenics' Improvement: Maybe It's the New Meds. Or Maybe Not.  // Behavior Analysis Digest International;Fall2010, Vol. 22 Issue 3, p12 

    The article discusses research on cognitive gains in schizophrenic patients given newer antipsychotic medications.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics